Compare Amgen, Inc. (AMGN) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Mongodb Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Mongodb Inc trades at $345 (market cap $27.51B). The key difference: Amgen, Inc. is far larger — about 7.1× Mongodb Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| AMGN | MDB | |
|---|---|---|
Market Cap | $196.12B | $27.51B |
Sector | Health | Technology |
52-Week High | $388.16 | $440.25 |
52-Week Low | $271.18 | $201.08 |
Enterprise Value | $241.41B | $25.12B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MongoDB (MDB) trades at $342.08, down 5.73% in the latest session, amid mixed technical signals with a bullish moving average trend but overbought RSI readings. The company shows strong revenue growth, reaching $2.01B in 2025, with consistent earnings beats in recent quarters, though it remains unprofitable with a net margin of -1.12%. Recent news highlights AI-driven demand boosting database sales and raised FY2027 revenue guidance to $2.92–$2.96B.
Outlook remains positive with 82% analyst buy ratings and a $400.39 consensus target, offering ~17% upside. Key risks include ongoing profitability challenges, competitive pressures, and legal scrutiny over fiduciary duties. Revenue growth and AI adoption present opportunities, but investors should monitor margin improvement and execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
